The use of SeptiCyte® RAPID can help physicians reach a sepsis diagnosis by delivering results in about one hour.
SEATTLE (PRWEB) September 10, 2020
Growing clinical evidence from hospitalized coronavirus patients worldwide indicates that COVID-19 can quickly progress to viral sepsis or bacterial sepsis, the most common complication of COVID-19 and a leading risk factor for mortality. The use of SeptiCyte® RAPID can help physicians reach a sepsis diagnosis by delivering results in about one hour, compared with the 12 to 24 hours required by a traditional lab test for sepsis. By determining if a patient has sepsis, clinicians can more quickly triage COVID-19 patients to urgent care and initiate the most appropriate treatment as soon as possible.
Developed by Immunexpress, SeptiCyte® RAPID works by testing blood biomarkers from the patient’s immune system to measure host response signals that serve as sepsis indicators. Highly accurate test results are delivered with a SeptiSCORE® that rates the likelihood of sepsis on a scale of zero to 15. The test results also differentiate infectious from non-infectious systemic inflammatory response syndrome (SIRS) in critically ill patients. In contrast, the traditional lab test for sepsis for identification of pathogens often yields inconclusive results.
“We developed SeptiCyte® RAPID because sepsis is a leading cause of death among hospitalized patients with a wide range of critical diseases. The COVID-19 pandemic has further highlighted the need for rapid identification and triage of all patients at risk of sepsis,” said Rolland D. Carlson, Ph.D., Chief Executive Officer of Immunexpress. “The sooner that physicians can identify patients at the highest risk and make an informed sepsis diagnosis, the faster they can administer the most effective treatments.”
About SeptiCyte® RAPID
SeptiCyte® RAPID uses a small vial of whole blood to test RNA rather than DNA genetic markers to rank the likelihood of a sepsis infection, enabling physicians to better interpret positive and negative pathogen results and make a faster sepsis diagnosis. As explained at septicyte.com, SeptiCyte® technology assesses a patient's dysregulated immune response by quantifying and analyzing gene expression, providing actionable results in about an hour. Physicians evaluate SeptiCyte® RAPID results in conjunction with other clinical assessments, vital signs and laboratory findings to diagnose bacterial sepsis, viral sepsis, or fungal infections, to differentiate infection-positive (sepsis) from infection-negative systemic inflammation, and to optimize patient management decisions.
Immunexpress is a groundbreaking molecular diagnostic company committed to improving outcomes for patients suspected of sepsis. Immunexpress developed SeptiCyte® to be incorporated easily into hospital labs and critical care triage and takes only an hour to run on tabletop equipment. The highly accurate results can help physicians make more informed patient management decisions, improve clinical outcomes and antibiotic stewardship, and lower healthcare costs related to sepsis. Founded in Australia and based in Seattle, Washington, Immunexpress is rolling out its SeptiCyte® technology worldwide. In March 2020, Immunexpress received CE Marking of SeptiCyte® RAPID and announced a long-term commercialization partnership with Biocartis in Europe.